Labcorp Welcomes Dr. John H. Sampson to Board of Directors

Dr. Sampson brings a wealth of experience to Labcorp from his current role as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine. Renowned as a neurosurgeon and physician-scientist, he possesses a robust background that encompasses clinical care, biomedical research, and medical education, which are critical components of Labcorp's mission. His specialization in oncology, neuroscience, women's health, and personalized medicine aligns seamlessly with the company's strategic focus areas.

Adam Schechter, Chairman and CEO of Labcorp, expressed enthusiasm over Dr. Sampson's appointment, stating, "John is widely respected as a leader in academic medicine, clinical practice, health system strategy, and research. His expertise will help advance Labcorp's strategy across diagnostics and drug development and enhance the value we deliver to customers."

Before his tenure at the CU Anschutz School of Medicine, Dr. Sampson held senior leadership positions at the Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. His accomplishments include being a practicing neurosurgeon, an esteemed member of the National Academy of Medicine, and the author of nearly 300 peer-reviewed publications, highlighting his commitment to advancing new therapies for neurological diseases.

In his new role at Labcorp, Dr. Sampson has been appointed to the Quality and Compliance Committee of the Board, a position that underscores the company’s commitment to maintaining high standards and regulatory compliance in its operations.

Reflecting on his new role, Dr. Sampson stated, "Labcorp plays a critical role in advancing earlier diagnosis, personalized medicine, and the development of new therapies. I look forward to contributing my clinical and research experience to help further the company’s mission of improving health and improving lives." This statement reinforces Labcorp's commitment to enhancing healthcare through innovation and scientific advancement.

Labcorp is recognized as a global leader in innovative laboratory services, providing critical insights that empower doctors, hospitals, pharmaceutical companies, researchers, and patients to make informed decisions. With nearly 70,000 employees serving clients in approximately 100 countries, Labcorp has played a pivotal role in supporting over 75% of new drugs and therapeutic products approved by the FDA in 2024. The company conducts more than 700 million tests annually, underscoring its extensive reach and impact in the healthcare sector.

As Labcorp continues to enhance its capabilities and offerings, the addition of Dr. Sampson to its Board of Directors is anticipated to significantly influence the company's trajectory in the evolving landscape of healthcare and diagnostics.